Analysis of Revenues
Revenues as Reported
AbbVie Inc., income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical products | 56,334) | 54,318) | 58,054) | 56,197) | 45,804) | ||||||
| Net revenues | 56,334) | 54,318) | 58,054) | 56,197) | 45,804) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Revenue Trends
- The annual revenue exhibits a generally positive trend over the analyzed period, with notable fluctuations. Starting from approximately 45.8 billion US dollars in 2020, the revenue increased significantly to about 56.2 billion US dollars in 2021, marking a substantial growth year-over-year.
- In 2022, the revenue growth continued but at a slower pace, reaching around 58.1 billion US dollars. This reflects a steady expansion in revenue compared to the previous year.
- However, a decline is observed in 2023 where revenue decreased to approximately 54.3 billion US dollars. This drop might indicate challenges such as market conditions, product lifecycle issues, or competitive pressures during that year.
- The revenue rebounded in 2024 to roughly 56.3 billion US dollars, indicating recovery and a return towards prior peak levels. Nevertheless, this value remains slightly below the 2022 peak.
- Overall, the data illustrates a growth trajectory over the five-year span with a temporary dip followed by partial recovery, suggesting resilience and potential strategic adjustments to stabilize revenue streams.